Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide for lupus during pregnancy.

M E B Clowse1, L Magder, M Petri

  • 1Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. meganclowse@hotmail.com

Lupus
|September 24, 2005
PubMed
Summary

Cyclophosphamide use in pregnant women with severe systemic lupus erythematosus (SLE) is associated with high fetal loss rates. This case series found all four pregnancies exposed to cyclophosphamide resulted in pregnancy loss, highlighting significant risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collapse of Nuclear Collectivity along the N=Z Line.

Physical review letters·2026
Same author

Author Correction: An asymmetric fission island driven by shell effects in light fragments.

Nature·2025
Same author

An asymmetric fission island driven by shell effects in light fragments.

Nature·2025
Same author

Electromagnetic properties of nuclei from first principles: a case for synergies between experiment and theory.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2024
Same author

Study of the N=32 and N=34 Shell Gap for Ti and V by the First High-Precision Multireflection Time-of-Flight Mass Measurements at BigRIPS-SLOWRI.

Physical review letters·2023
Same author

The clinical and serological associations of hypocomplementemia in a longitudinal sle cohort.

Seminars in arthritis and rheumatism·2020

Area of Science:

  • Obstetrics & Gynecology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) management in women of reproductive age often involves cyclophosphamide.
  • Cyclophosphamide use during pregnancy is limited due to teratogenic risks, leaving its impact on fetal survival poorly understood.

Observation:

  • A case series reviewed four pregnancies in lupus patients exposed to cyclophosphamide between 1986 and 2003.
  • Two pregnancies experienced inadvertent first-trimester exposure, resulting in miscarriages.
  • Two patients received second-trimester cyclophosphamide for severe lupus nephritis and thrombocytopenia, leading to fetal demise.

Findings:

  • All four pregnancies exposed to cyclophosphamide resulted in fetal loss (100% fetal loss rate).
  • Pregnancies requiring cyclophosphamide for severe lupus flares had a significantly higher fetal loss rate compared to those not requiring the drug (100% vs. 31.25%).

Related Experiment Videos

Implications:

  • Cyclophosphamide treatment for severe lupus during pregnancy poses a substantial risk to fetal survival.
  • Further research is needed to explore safer treatment alternatives for lupus during pregnancy.